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ABSTRACT
Transcription–replication (T–R) conflicts are pro-
found threats to genome integrity. However, whilst
much is known about the existence of T–R conflicts,
our understanding of the genetic and temporal nature
of how cells respond to them is poorly established.
Here, we address this by characterizing the early cel-
lular response to transient T–R conflicts (TRe). This
response specifically requires the DNA recombina-
tion repair proteins BLM and BRCA2 as well as a non-
canonical monoubiquitylation-independent function
of FANCD2. A hallmark of the TRe response is the
rapid co-localization of these three DNA repair fac-
tors at sites of T–R collisions. We find that the TRe
response relies on basal activity of the ATR kinase,
yet it does not lead to hyperactivation of this key
checkpoint protein. Furthermore, specific abrogation
of the TRe response leads to DNA damage in mito-
sis, and promotes chromosome instability and cell
death. Collectively our findings identify a new role for
these well-established tumor suppressor proteins at
an early stage of the cellular response to conflicts
between DNA transcription and replication.
INTRODUCTION
Faithful replication of the genome is of utmost impor-
tance to sustain life and prevent genetic diseases like can-
cer. During replication, DNA polymerases meet numer-
ous challenges including DNA damage and collision with
RNA polymerases. Failure to successfully overcome these
inevitable challenges during replication can manifest as ge-
nomic instability––a hallmark of cancer (1,2). To deal with
disruption of DNA replication, cells may initiate a so-called
replication stress response (3), which is characterized by ac-
tivation of the ATR checkpoint kinase and subsequent cell
cycle arrest. Whilst cell cycle arrest may be a desired re-
sponse to various challenges, each type of replication im-
pediment also requires a distinct action to be overcome.
Yet, our current knowledge of pathway choice at stalled
replication forks is limited. This is in part because fork
stalling may lead to fork collapse, which is accompanied by
a DNA damage response that masks the initial response to
stalled forks (4). In particular the early cellular response to
transcription–replication (T–R) conflicts has been difficult
to study due to a lack of methods to rapidly and specifically
induce endogenous T–R collisions.
Normally, transcription and replication are coordinated
to minimize T–R conflicts (5). However, cancer cells are
characterized by deregulated replication (4), rapid cell di-
vision (1) and widespread transcriptional activation collec-
tively laying the grounds for frequent T–R collision (6).
Moreover, T–R conflicts are inevitable at the largest genes
in the genome because it takes more than one cell cycle to
complete transcription of these genes (7). Under conditions
of replication stress, transcription of large genes results in
breaks at these specific regions on metaphase chromosomes
known as common chromosomal fragile sites (CFSs) (8–
10). It is likely that T–R conflicts that persist into mitosis
contribute substantially to mutagenesis in cancer since re-
gions of the genome that face commonT–R conflicts includ-
ing CFSs are hotspots for large deletions in a broad range
of cancer genomes (7,11–15). However, it is unclear how T–
R conflicts can go unnoticed intomitosis without activating
cell cycle checkpoints.
Mechanistically, T–R conflicts probably occur via the for-
mation of so-called transcriptional RNA–DNA hybrids,
where nascent RNA hybridizes back to the complemen-
tary DNA template forming an RNA–DNA hybrid that
displaces the non-coding strand of the DNA duplex. This
structure is often referred to as an R loop. Specifically,
RNA–DNA hybrids can cause replication stress, DNA
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breaks, chromosomal rearrangements, and chromatin al-
terations (16–18). Several cellular pathways keep levels of
RNA–DNA hybrids in check. Firstly, RNase H1 and he-
licases actively degrade or remove RNA–DNA hybrids, re-
spectively (19). Secondly, RNAmaturation and splicing fac-
tors as well as topoisomerase I prevent accumulation of
RNA–DNAhybrids (19).Moreover, disruption ofDNA re-
pair factors, BRCA1, BRCA2, FANCA, FANCM, BLM
and RECQL5 leads to accumulation of RNA–DNA hy-
brids but it is unclear how these factors prevent nuclear
buildup of RNA–DNA hybrids (17,20–23).
Investigation of specific CFSs showed accumulation of
RNA–DNA hybrids in the absence of FANCD2 suggest-
ing that FANCD2 may have a role at T–R conflicts (24–
27). Moreover, purified chicken FANCD2 has high affin-
ity for RNA–DNA hybrids (28), whereas human FANCD2
together with its binding partner FANCI binds the single-
stranded DNA that forms as part of the R loop (29). The
FANCD2 gene is one of 23 genes that whenmutated give rise
to the recessive genetic disorder Fanconi Anemia (FA). At
the cellular level FA is characterized by hypersensitivity to
chemotherapeutic DNA crosslinking agents and aldehydes
(30). The role of FANCD2 inDNA interstrand crosslink re-
pair is well characterized. It involves FANCD2 monoubiq-
uitylation by a large E3 ubiquitin ligase complex where
FANCL is the catalytic subunit (31–33). Many FA genes di-
rectly take part in the crosslink repair pathway, but others
seem to act in parallel or downstream. This includes the tu-
mor suppressor protein BRCA2 (also known as FANCD1)
(34,35), which plays an important role during homologous
recombination (36,37) and also works as a fork stabilizer
(38). FANCD2 works together with the helicases BLM and
FANCJ as well as BRCA2 to promote fork restart after
hydroxyurea- or aphidicolin-mediated fork stalling (39,40).
BLM is a tumor suppressor, which is mutated in a rare
recessive genetic disorder called Bloom’s syndrome, which
is characterized by dramatic hyper-susceptibility to a wide
range of cancers (41).
mRNA in eukaryotes is synthesized by RNA polymerase
II (RNAP II). RNAP II pauses 20–100 base pairs down-
stream of the transcription start site (42–44). Here, P-
TEFb (45), which is composed of cyclin T and Cdk9,
phosphorylates Serine 2 (Ser2) of the carboxy-terminal do-
main repeat (CTD) of RNAP II to trigger the initiation-to-
elongation transition (43,46). Pausing of RNAP II causes
R-loop formation (47), which in turn may explain why
promoter/5′UTR regions are genomic hotspots for R loops
(48,49).
The early cellular response toT–R conflicts has been diffi-
cult to study due to a lack of methods to rapidly and specif-
ically induce endogenous T–R collisions. Here we take ad-
vantage of Cdk9 inhibitors to investigate the cellular re-
sponse to T–R conflicts. Using this approach, we find that
T–R conflicts induce early colocalization of the recombina-
tion factors BRCA2, FANCD2 and BLM into nuclear foci
and each of these factors are required for survival after tran-
sient induction of T–R conflicts, because they prevent T–R
conflicts from escalating into genomic instability in mitotic
cells. We furthermore provide insight into how T–R con-
flicts escape cell cycle arrest, as we find that they do not lead
to activation of the ATR checkpoint kinase.
MATERIALS AND METHODS
Cell culture and transient transfection
DT40 cells were cultured in RPMI 1640 medium Glu-
taMAX (ThermoFisher Scientific) supplemented with 2%
chicken serum (Sigma-Aldrich), 8% fetal bovine serum
(ThermoFisher Scientific), 50 M -mercaptoethanol, 50
U/ml penicillin, and 50 g/ml streptomycin at 39◦C with
5% CO2.
U2OS cells were maintained in McCoy’s 5A modified
medium (ThermoFisher Scientific) supplemented with 10%
fetal bovine serum, 50 U/ml penicillin and 50 g/ml strep-
tomycin (15070063, ThermoFisher Scientific) at 37◦C with
5% CO2. For transient transfection, the Amaxa system
(Nucleofector, Lonza) was used as previously described
(50). PD20 (FA-D2) (51) and PD20 complemented cells de-
scribed in (52) were maintained in DMEM+GlutaMAX
medium (ThermoFisher Scientific) supplemented with 15%
fetal bovine serum, 50 U/ml penicillin, 50 g/ml strepto-
mycin, and 2 g/ml Blasticidin S HCl (ThermoFisher Sci-
entific) at 37◦C with 5% CO2.
Live cell and immunofluorescence microscopy
Live cell microscopy was performed as previously described
(53) using a wide-field microscope (Deltavision Elite, GE
Healthcare) equipped with a 100× oil objective lens with
a numerical aperture of 1.35 (GE Healthcare). Briefly, im-
ages were taken with 8 optical sections separated by 0.5
m. Exposure times and excitation light intensities were
optimized for each fluorophore. Fifteen minutes before
imaging, 40 l of DT40 cell culture were transferred to a
-slide microscopy chamber (1 -slide Angiogenesis ibi-
Treat, Ibidi). As indicated in the figures, the following drugs
were added for the indicated time before imaging: 1 M
flavopiridol (S1230, Selleckchem), 100 nM AZ20 (S7050,
Selleckchem), ATMi 1 M (S1570, Selleckchem), 50 M
DRB (D1916, Sigma-Aldrich), 100 nM Cisplatin (Sigma-
Aldrich), 1 M PladB (445493-23-2, Santa Cruz), 200 nM
CHIR-124 (S2683, Selleckchem), 1M MC-180295 (PC-
35808, Probechem) or 100 nM CPT (7689-03-4, Sigma-
Aldrich). Immunofluorescence microscopy of DT40 cells
was performed at room temperature using the wide-field
microscope (Deltavision Elite) as described above. For im-
munofluorescence, DT40 cells were allowed to set on poly-
lysine covered coverslip for 10 min before fixation with 4%
paraformaldehyde. Cells were blocked in PBS-T (PBS with
0.1% Tween 20) with 3% Bovine Serum Albumin (A0281,
Sigma-Aldrich) for 1 h before overnight incubation with
primary H2AX antibody (1:500, 05-636, Millipore) at
4◦C. Unbound primary antibodies were removed by wash-
ing three times for 5 min in PBS followed by incubation
with secondary antibody (1:500, Alexa555 anti-mouse IgG
A21422, Life Technologies) for 50 min. Coverslips were
then washed three times for 5 min in PBS before mount-
ing with mounting medium containing DAPI (4% n-propyl
gallate, 80% glycerol, 1 g/ml DAPI). For quantification
of the S9.6 mean fluorescence intensity, cells were extracted
with 100% ice-cold methanol for 10 min, followed by 100%
ice-cold acetone for 1 min, and then RNases III (1:200,
AM2290, ThermoFisher Scientific) andT1 (1:200, EN0541,
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ThermoFisher Scientific) was added followed by 5% bovine
serum albumin (BSA) and 0.2% milk in PBS for 1 hour
blocking. Samples were incubated with the S9.6 antibody
(1:500, ENH001, Kerafast) in blocking buffer overnight
at 4◦C, and washed by PBS three times for 5 min. Sec-
ondary antibody staining and mounting was done as de-
scribed above.
Images were processed and quantitative measurements
of fluorescence intensities and foci were performed using
Volocity software (PerkinElmer). Images were pseudocol-
ored according to the approximate emission wavelength
of the fluorophores. Fluorescent proteins used in DT40
were TFP (pmTurquoise2-N1 (54)), eYFP (enhanced YFP,
Takara Bio Inc.), Venus (55), and mCherry (56).
For measuring the percentage of H3 phospho-Ser10-
positive cells in DT40 cell, cells are harvested and washed
with cold PBS, fixed with 70% EtOH at −20◦C for
overnight, followed by two PBS washes, and then incuba-
tion of the pellet in pS10H3 antibody solution (1:40, 06-570,
Millipore) at room temperature for 2 h. Secondary antibody
staining andmounting was done followed by pipetting 40l
of stained cell culture into Xcyto 2-chamber slide. Images
were processed and quantitative measurement of fluores-
cence intensities was performed usingXcyto 10 (ChemoMe-
tec).
For immunofluorescence microscopy of U2OS cells,
asynchronous cultures were grown on coverslips. Cells were
blocked in PBS-T (PBS with 0.1% Tween20) with 3% BSA
(A0281, Sigma-Aldrich) for 1 h before overnight incubation
with primary FANCD2 antibody (NB100-182SS, Novus
Biologicals) at 4◦C. Unbound primary antibodies were re-
moved by washing three times for 5 min in PBS followed
by incubation with Alexa 568 goat anti-rabbit IgG sec-
ondary antibody (1:500, A11011, Life Technologies) for 50
min. Coverslips were then washed three times for 5 min in
PBS before mounting with mounting medium containing
DAPI (4% n-propyl gallate, 80% glycerol, 1 g/ml DAPI).
In situ proximity ligation assay (PLA) was performed fol-
lowing instructions fromDuolink PLA technology (Sigma-
Aldrich) with the minor change that cells were treated with
pre-extraction buffer (10 mM Tris–HCl pH 6.8, 2.5 mM
MgCl2, 0.5% NP-40 and 1 mM PMSF) prior to blocking.
5-Ethynyl uridine (EU) incorporation was performed with
reagents from Click-iT EdU kit (C10637, ThermoFisher
Scientific) in accordance with the manufacturer’s instruc-
tions. 120 mM of EU (E10345, ThermoFisher Scientific)
was used for nascent transcripts detection. Images were ac-
quired using the wide-field microscope (Deltavision Elite)
as described above.
DT40 cell lines
DT40 cell lines used in this study are listed in supplemental
table S1. For stable transfections, constructs were electropo-
rated into DT40 cells (Gene Pulser Xcell, BioRad). Trans-
fectants harbouring the PURO, BSR, NEO and HYG re-
sistance genes were selected in the presence of 0.5 g/ml
puromycin (A11138-03, Life Technologies), 20 g/ml blas-
ticidin S (A11139-03, Life Technologies), 2 mg/ml G418
(CP11.3, Roth) or 2.0 mg/ml Hygromycin B (10687010,
Thermo Fisher Science), respectively. Dilution cloning was
used for selecting positive single clones. Clones were tested
by fluorescence microscopy, and positive clones were cul-
tured in DT40 medium with relevant drug selection. All re-
sistance cassettes were flanked by LoxP sites and floxed as
described previously (57). In brief, cell lines were transiently
transfected with cDNA encoding the Cre recombinase and
subsequently dilution cloned to obtain single colonies. Loss
of selection markers was tested by treating the resulting cell
lines with puromycin, G418, or blasticidin. In this study,
Gallus gallus genes were endogenously tagged at their 3′ ter-
minal except for FANCD2, which was tagged at the 5′ ter-
minus.
Plasmids
Plasmids and primers used in this study are listed in Supple-
mental Table S2 and S3, respectively. The plasmid for over-
expression of RNase H1 was generated by PCR amplifying
the cDNA with BglII or SalI adapted primers VO317 and
VO318 for directional cloning into pmCherry-C1 (Clon-
tech, Takara). Human RNase H1 cDNA in pENTR221
plasmid (Ultimate ORF clones, IOH4870, ThermoFisher
Scientific) was used as a template. Correct PCR amplifica-
tion was verified by sequencing.
The plasmid pmCherry-BLM was generated by lifting
the G. gallus BLM cDNA as a BamHI fragment from
EGFP-gallusBLM (58) into the BamHI site in pmCherry-
C1 (Clontech, Takara). Quikchange II Site-Directed Mu-
tagenesis (#200523, Agilent) was used to generate Walker
A motif mutant of G. gallus BLM cDNA K663T in ac-
cordance with the Instruction manual (primers for BLM
K663T: VO336 and VO337). All constructs were verified by
sequencing.
The targeting vector for endogenous C-terminal tagging
of BRCA2 (Gene ID: 418915) was constructed by first
PCR amplifying the 5′ homology arm using genomic DT40
DNA as a template with a KpnI adapted forward primer
(LJ01) and a XhoI adapted reverse primer (LJ02). The 3′
homology arm was then amplified by PCR using a BcuI
adapted forward primer (LJ03) and a NotI adapted re-
verse primer (LJ04). eYFP or TFP was amplified using
peYFP-C1 (Clontech, Takara) or pmTurquoise2-N1 (54) as
template, respectively, with a SalI adapted forward primer
(LJ05) and a SmaI adapted reverse primer (LJ06). Frag-
ments were subcloned into pBlueScript SK+ (Fermentas)
by directional cloning. The puromycin or blasticidin (BSR)
resistance cassettes, flanked by lox sequences were inserted
into the BamHI restriction site.
Colony survival assay
DT40 cells were treated with drugs before seeding in methyl
cellulose medium (59). The plates were then incubated in a
humid box in a CO2 incubator at 37◦C until the colonies
were clearly visible and countable. Survival is plotted as a
percentage of the colonies forming in the untreated control.
Experiments were repeated three times.
PD20 and complemented cells were plated in 6-well plates
and incubated in a CO2 incubator at 37◦C for 24 h. The me-
dia was replaced by DMSO media or 1 M flavo media.
After treatment for the indicated time, the drug-containing
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media was removed and fresh warmmedia was added. Cells
were incubated for 8–10 days, washed in PBS, stained with
0.5% crystal violet in 25% methanol for 2 min. Plates were
rinsed with ddH2O. The plates were scanned and resulting
images analysed by calculating the colony area according
the published protocol (60). Survival is plotted as a percent-
age of the colonies area in the DMSO treated control. Ex-
periments were repeated three times.
Metaphase spreads
Cell cultures were treated with 1 M flavo for 1 h after
which cells were washed and resuspended in prewarmed
medium. Colcemid (Life Technologies) at a concentration
of 0.1 g/ml was added 150 min before harvest. Next, cells
were swelled in 8 ml hypotonic buffer (20% FBS [v/v], 15
mMKCl) for 15 min. Next, 10 ml fixation buffer (25% ace-
tone, 75% methanol) was added drop by drop. Cells were
harvested by centrifugation at 1000 rpm for 5 min, followed
by resuspension in 10 ml fixation buffer. Cells were stored
at−20◦C for 2 days. Finally, the cells were splatted onto the
slides and mounted with cover slips using 5 l of mounting
medium containing DAPI (4% n-propyl gallate, 80% glyc-
erol, 1g/mlDAPI).Metaphase chromosomes were visual-
ized on a widefield microscope (AxioImager Z1; Carl Zeiss)
equippedwith a 100× objective lens (PlanApochromat,NA
1.4; Carl Zeiss), a cooled CCD camera (Orca-ER; Hama-
matsu Photonics), differential interference contrast (DIC),
and an illumination source (HXP120C; Carl Zeiss);
FACS sorting
DT40 cells were stained by Vybrant Ruby Stain (5 M,
V10309, ThermoFisher Scientific) at 37◦C for 15 min, pro-
tected from light according to manufacturer’s protocol. 20
000 cells from G1, S and G2/M phase were sorted using
FACSJazz (BD Biosciences) system with 561 nm excitation
and >670 nm emission. Sorted cells were then incubated in
pre-warmed RPMI medium for further treatment.
Dot blot
Genomic DNA was extracted using Genomic DNA extrac-
tion kit (51306, Qiagen). Next, genomic DNA was precipi-
tatedwith isopropanol, washedwith 70% ethanol, air-dried,
and resuspended in Tris-EDTA (TE) buffer. Half of the
DNA was treated with RNases III and T1 and half was
treated with RNases III, T1 and H1 (M0297L, NEB), at
37◦C for 6 h. Equal amounts of DNA were blotted onto a
Hybond H+ membrane (RPN203B, GE Healthcare) using
a dot blot apparatus (Bio-Rad). The membrane was dried
overnight at room temperature and DNA was cross-linked
to the membrane using UV. The membrane was blocked
with 5% skimmed milk in PBS-T and incubated with S9.6
antibody (1:500, ENH001, Kerafast) and dsDNA antibody
(1:5000, ab27156, Abcam), followed by incubation with sec-
ondary antibody (1:2000, P0161, Dako). The membrane
was incubated with ECL reagents (RPN 2109, GE) for 3
min. The ECL signal was recorded using an ImageQuant
LAS 4000 (GEHealthcare). ImageJ (NIH)was used for pic-
ture processing, and quantification of S9.6 mean intensity.
Western blot
For Western blot analysis, cells were lysed in RIPA buffer
(1% NP40, 0.5% Na deoxycholate, 0.1% SDS in 1× PBS)
in the presence of protease inhibitor cocktail (Roche) by
syringing eight times through a 25 G needle. Lysates
were cleared by centrifugation at 10 000 g for 10 min.
Samples were separated by SDS-PAGE on 8% polyacry-
lamide Tris-glycine gels for FANCD2 or 4–20% Tris-
glycine gels (mini-Protean TGX, #456-1093, Bio-Rad) for
all other western blots. For analysis of monoubiquity-
lation of Venus-FANCD2, mouse anti-GFP monoclonal
(1:500, 11814460001, Roche) and anti-mouse IgG conju-
gated to HRP (1:2000, P0161, Dako) were used as pri-
mary and secondary antibodies, respectively. For analy-
sis of CHK1-Ser345P, rabbit anti-phospho Ser345 -CHK1
(1:1000, #2348, Cell Signaling), and anti-rabbit IgG con-
jugated to HRP (1:2000, P0217, Dako) were used as pri-
mary and secondary antibodies, respectively. For analy-
sis of CHK1, mouse anti-CHK1 (1:2000, sc-8408, Santa
Cruz), and anti-mouse IgG conjugated to HRP (1:2000,
P0161, Dako) were used as primary and secondary anti-
bodies, respectively. For analysis of MCM2-Ser108P, rabbit
anti-phospho MCM2 S108 antibody (1:1000, A300-094A,
Bethyl), and anti-rabbit IgG conjugated to HRP (1:2000,
P0217, Dako) were used as primary and secondary antibod-
ies, respectively. For analysis ofMCM2,mouse anti-MCM2
(1:1000, sc-373702, Santa Cruz), and anti-mouse IgG con-
jugated to HRP (1:2000, P0161, Dako) were used as pri-
mary and secondary antibodies, respectively. For analysis of
ATM-pS1981, rabbit anti-phospho-ATM (1:1000, Ser1981,
ab81292, Abcam), and anti-rabbit IgG conjugated to HRP
(1:2000, P0217, Dako) were used as primary and secondary
antibodies, respectively. For analysis of ATM, mouse anti-
ATM (1:1000, sc-135663, Santa Cruz), and anti-mouse IgG
conjugated to HRP (1:2000, P0161, Dako) were used as
primary and secondary antibodies, respectively. For anal-
ysis of CHK2-Thr68P, rabbit anti-phospho Thr68 -CHK2
(1:1000, cst2197t, BioNordika), and anti-rabbit IgG con-
jugated to HRP (1:2000, P0217, Dako) were used as pri-
mary and secondary antibodies, respectively. For analy-
sis of RNAP ll CTD Ser2 phosphorylation and RNAP ll
CTD Ser5 phosphorylation, RNAP ll CTD Ser2 antibody
(1:1000, MABE953, Merckmillipore), RNA pol ll CTD
Ser5 antibody (1:1000, 04-1572, Merckmillipore), and anti-
Rat IgG conjugated to HRP (1:2000, P0450, Dako) were
used as primary and secondary antibodies, respectively.
Chromatin immunoprecipitation (ChIP)-qPCR
DT40 cultures (5 × 107 cells) were treated as indicated
(1 M flavo or DMSO for 40 min) and fixed for 10 min
with 1×Crosslink Buffer (0.75%paraformaldehyde, 10mM
NaCl, 50MEGTA and 5mMHEPES pH 8.0). Then fixa-
tion was stopped by addition of glycine to a final concentra-
tion of 125 mM and incubate for 5 min. Cells were washed
with 1 X PBS twice and resuspended in 4 ml of SDS buffer
(100 mMNaCl, 50 mMTris-Cl pH 8.0, 5 mMEDTA, 0.1%
SDS,10 mM glycerol-phosphate, protease inhibitor cock-
tail (11697498001, Merck) and 2 mM PMSF). Lysates were
sonicated for 2 min using a Sonicator (Misonix) and cen-
trifuged at 20 000 rpm for 10min at 4◦C.At this point, 1%of
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supernatant was saved for ‘Input’, the rest of sample was di-
luted with 1 ml Triton dilution buffer (100 mM Tris–Cl pH
8.6, 100 mMNaCl, 5 mMEDTA pH 8.0, 5% Triton X-100,
1 mM Na3VO4 and protease inhibitor cocktail). Diluted
lysates were incubated with antibodies (RNAP II CTD
Ser2P or RNAP II CDT Ser5P) rotating overnight at 4◦C.
Dynabeads Protein G (10004D, ThermoFisher Scientific)
were added to antibody-chromatin mixture, and incubated
on a rotating wheel for 2 h at 4◦C. Beads were washed twice
with Wash Buffer I (1% Triton X-100, 0.1% SDS, 150 mM
NaCl, 2 mMEDTA pH 8.0 and 20mMTris–Cl pH8.0), fol-
lowed by one wash with Wash Buffer II (1% Triton X-100,
0.1% SDS, 500 mMNaCl, 2 mMEDTA pH 8.0 and 20 mM
Tris–Cl pH 8.0). Beads were resuspended in 150 l freshly
prepared Elution buffer (1% SDS and 0.1 M NaHCO3
pH 8.0) at 65◦C for 30 min. Input samples and eluates were
incubated with 2 MNaCl and 150 g/ml RNase A at 65◦C
overnight, followed by addition of 0.1 mg/ml Protease K
at 60◦C for 1 h. DNA was purified using the GeneJET
PCR Purification kit (K0702, ThermoFisher Scientific). Se-
quences of the primers used for qPCR are shown in sup-
plementary Table S3, GAPDH amplicon 1 primers (VO355
and VO356), amplicon 2 primers (VO357 and VO358), am-
plicon 3 primers (VO359 and VO360); SMC2 amplicon 1
primers (VO361 and VO362), amplicon 2 primers (VO363
and VO364), amplicon 3 primers (VO365 and VO366). Re-
actions were run using Maxima SYBR Green/ROX qPCR
Master Mix (K0222, ThermoFisher Scientific). All qPCR
was performed by using a CFX96 Real-Time PCR Detec-
tion system (Bio-Rad). The dilution factorwas adjusted and
the percentage of the input was calculated.
DNA–RNA immunoprecipitation (DRIP)
DRIP-qPCR experiments were performed based on the
published protocol (61). Briefly, genomic DNA was ex-
tracted using phenol–chloroform extraction. Then, DNA
was fragmented using a restriction enzyme cocktail (EcoRI,
HindIII, XbaI, SspI and BSrGI (NEB)). Half of the sam-
ple was digested with RNase H1 (M0297L, NEB) and the
other half was treated with RNase III (AM2290, Ther-
moFisher Scientific) for 6 h at 37◦C. Fragmented DNA
was purified with phenol–chloroform extraction and re-
suspended in TE buffer (10 mMTris pH 8.0, 1 mMEDTA).
RNA–DNA hybrids were immunoprecipitated from total
nucleic acids using 5 g of the S9.6 antibody in 1× bind-
ing buffer (10 mM NaPO4 pH 7.0, 140 mM NaCl, 0.05%
Triton X-100) overnight rotating incubation at 4◦C. 40 l
pre-washed Dynabeads conjugated to Protein G (10003D,
ThermoFisher Scientific) were added to the hybrids and an-
tibody mixture and incubated for 2 h at 4◦C on a rotator.
Isolated complexes were washed three times with 1× bind-
ing buffer before elution with 120 l of elution buffer (50
mM Tris pH 8.0, 10 mM EDTA, 0.5% SDS). Proteinase K
digestion was performed at 55◦C for 45 min, followed by
PCR purification kit (K0702, ThermoFisher Scientific) ex-
traction, and eluted in 150 l TE buffer. The relative occu-
pancy of the immunoprecipitatedDNA–RNAhybrid at the
specified sites in the SAE1 gene was determined by qPCR
with the primers described in Table S3, SAE1 amplicon 1
primers (XS69 and XS70), amplicon 2 primers (XS71 and
XS72), amplicon 3 primers (XS79 and XS80), amplicon
4 primers (XS81 and XS82). The results were normalized
against input DNA.
Statistical methods
For microscopy experiments, the significance of the differ-
ences between cell populations was determined by a two-
tailed unpaired t-test. P-values were defined as significant
if P < 0.05. Error bars representing 95% confidence in-
tervals were calculated by Prism 7 (GraphPad Software).
For colony survival assay, the significance of the differ-
ences between groups was determined by two-tailed un-
paired t-test. P-values were considered significant if P <
0.05. Error bars represent standard deviations. Three in-
dependent experiments were carried out to generate each
data set.
RESULTS
FANCD2 is important for survival after transient block of
RNAP II promoter proximal release
The drugs flavopiridol (flavo), DRB and MC180295
(MC295) are Cdk9 inhibitors that prevent phosphoryla-
tion of Ser2 in RNAP II CTD, thereby blocking the tran-
sition from transcription initiation to transcription elonga-
tion (62,63). As a consequence, Cdk9 inhibitors trap RNAP
II near the promoter (64), which can potentially block an
advancing replication fork. We confirmed the efficiency of
Cdk9 inhibition by flavo andMC295 in our model systems,
DT40 and U2OS, by western blot of the Cdk9 substrate
RNAP II CTD Ser2P (Supplementary Figure S1A,B). As
expected, Cdk9 inhibition also resulted in overall transcrip-
tion inhibition as measured by decreased EU incorporation
(Supplementary Figure S1C). It was previously shown that
the promoter proximal paused RNAP II is stabilized with
flavo or DRB treatment (65). Phosphorylation of Serine 5
(Ser5P) of the CTD of RNAP II precedes phosphoryla-
tion of RNAP II CTD Ser2 (43). We confirmed by ChIP of
RNAP ll CTDSer5P followed by qPCR that a large propor-
tion of paused RNAP II (at amplicon 1) was still retained
at the promoter regions of GAPDH or SMC2 gene after 40
min flavo treatment, whereas RNAP II CTD Ser5P at the
gene body disappeared as expected (Supplementary Figure
S1D, right). Also, as expected, RNAP II CTD Ser2P disap-
peared at both promoter region and gene body (Supplemen-
tary Figure S1D, left). The mild decrease of RNAP II CTD
Ser5P at the first amplicon upon flavo addition may be a re-
sult of suppression of new transcriptional initiation by the
paused RNAP II (65,66). To characterize the early cellular
effects of Cdk9 inhibition we investigated whether known
markers of CFSs, DNA double-strand breaks (DSBs) and
replication stress (FANCD2 (25,26) and TopBP1 (53,67,68)
change localization pattern in response to flavo, DRB and
MC295. Intriguingly, all drugs induced a small but sig-
nificant increase in FANCD2 focus formation that peaks
around 30 or 60 min, after which the number of foci gradu-
ally decrease to levels below that observed in the untreated
cell line (Figure 1A). Importantly, the overall level of Venus-
FANCD2 does not change within the two-hour flavo treat-
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ment (Supplementary Figure S1E). The level of TopBP1
foci is not affected by flavo or DRB (Supplementary Fig-
ure S2A,B), indicating that no immediateDSBs or extensive
single-stranded DNA (ssDNA) are formed (69,70). 53BP1
is aDSB repair factor and aG1marker of replication stress-
induced DNA damage inherited from the previous S phase
(71). Consistently, flavo-induced FANCD2 foci do not colo-
calize with 53BP1 (Supplementary Figure S2C, D). Flavo-
mediated induction of FANCD2 foci was also observed by
immunostaining in human U2OS cells (Figure 1B).
To address whether FANCD2 is important for cellular
survival after transient treatment with Cdk9 inhibitors, we
performed colony survival of DT40 FANCD2−/− cells after
drug treatment for one hour. The interstrand crosslinker cis-
platin was used as control. Whilst the DT40 parental cells
(referred to as ‘wild-type’ (WT))were not sensitive to the ap-
plied concentrations of the drugs, FANCD2−/− cells were
indeed sensitive demonstrating that FANCD2 is required
for survival after transient treatment with Cdk9 inhibitors
(Figure 1C).
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RNAP II stalling at promoter proximal sites leads to T–R
conflicts
The important roles of FANCD2 at stalled replication forks
(40,72,73) suggest that Cdk9-inhibitor-induced FANCD2
foci mark T–R conflicts. If that were the case, we would
expect that flavo-mediated induction of FANCD2 foci oc-
curs mainly in S phase. To test this idea, we FACS sorted
cells from G1, S, and G2/M phases of the cell cycle be-
fore subjection to a one-hour flavo treatment (Supplemen-
tary Figure S2E). This revealed that flavo-mediated induc-
tion of FANCD2 foci indeed is restricted to S phase (Fig-
ure 2A). Moreover, we found that G1 cells were resistant to
a one-hour treatment with flavo whereas S-phase cells and,
surprisingly, also G2/M cells were sensitive to flavo (Figure
2B). This could indicate that induction of T–R conflicts at
late stages of the replication process, which sometimes con-
tinues in G2 and even M (53,74,75), may be detrimental.
To directly test whether Cdk9 inhibition triggers T–R
conflicts we employed the proximity ligation assay (PLA)
on fixed U2OS cells using anti-PCNA and anti-RNAP ll
Ser5P antibodies. A striking increase of PLA foci at 30 min
flavo treatment compared to DMSO treatment was evident,
and this increase disappeared by 60 or 120 min flavo treat-
ment (Figure 2C,D). Since RNAP II Ser5P is mainly found
at the 5′ end of genes this strongly suggests an increase in
T–R conflicts at promoter proximal pause sites shortly af-
ter Cdk9 inhibition. As expected, 60min inhibition of Cdk9
by flavo leads to a severe reduction of RNAP II Ser2P and
PCNA PLA signal (Supplementary Figure S2F) consistent
with the flavo-induced reduction of RNAP II CTD Ser2P
(Supplementary Figure S1A,B).
FANCD2 foci induced by Cdk9-inhibition depend on RNA–
DNA hybrids
DRB has been shown to induce RNA–DNA hybrids at
promoter proximal regions (64), which suggest that RNA–
DNA hybrids underlie T–R conflicts induced by Cdk9
inhibition. Therefore, we asked whether flavo also in-
duces RNA–DNA hybrids that may mediate its effect on
FANCD2 localization. We used dot blotting and immunos-
taining with the S9.6 antibody that recognizes RNA–DNA
hybrids (Figure 3A, B and Supplementary Figure S3A) (76).
Both methods showed that DT40 WT and FANCD2−/−
cells have increased levels of RNA–DNA hybrids when
treated with flavo. Untreated FANCD2−/− cells displayed
significantly higher levels than the untreated WT, consis-
tent with previous work showing constitutive higher RNA–
DNA hybrid levels in FANCD2-deficient cells (21). More-
over, we performed ChIP-qPCR at the SAE1 gene, which
was previously reported to accumulate RNA–DNAhybrids
at the transcription start site upon DRB treatment (64).
This analysis showed that flavo induces RNA–DNA hy-
brids around the transcription start site of SAE1 (Figure
3C), suggesting that RNA–DNA hybrids are induced at
promoter proximal regions by flavo similarly to DRB (64).
To determine whether flavo-induced FANCD2 focus
formation was dependent on RNA–DNA hybrids, we
transiently overexpressed mCherry-tagged RNase H1 and
quantified FANCD2 foci in transfected and untransfected
cells (with or without red fluorescence, respectively). Unlike
untransfected cells, a flavo-induced increase in FANCD2
foci was not observed in cells expressing RNase H1, sug-
gesting that RNA–DNA hybrids lead to flavo-induced
FANCD2 focus formation (Figure 3D, E).
The early cellular response to T–R conflicts does not involve
FANCD2 monoubiquitylation or ATR activation
FANCD2 focus formation in response to DNA damage
is normally accompanied by its monoubiquitylation, but
we found that Cdk9 inhibitors did not induce FANCD2
monoubiquitylation in contrast to control treatment with
the topoisomerase I poison, camptothecin (CPT) (Figure
4A). To firmly establish whether FANCD2 monoubiquity-
lation is important for the role of FANCD2 at T–R con-
flicts, we determined the sensitivity of FANCD2-K563R
cell line to flavo. We also included a cell line with knock-
out of the FANCD2 binding partner FANCI. The inter-
strand crosslinking agent mitomycin C was used as a con-
trol. Neither FANCD2-K563R nor FANCI−/− cells were
sensitive to flavo treatment (Figure 4B), FANCL is the cat-
alytic subunit of the E3 ubiquitin ligase complex respon-
sible for monoubiquitylation of FANCD2. In agreement
with the resistance of the FANCD2 monoubiquitylation
mutant, FANCL−/− cells were not sensitive to these drugs
but showed the expected sensitivity to cisplatin (Supplemen-
tary Figure S3B). Moreover, the cell line PD20, which is a
FANCD2 deficient cell line derived from a FA patient (51)
was more sensitive to 2 or 4 h of flavo treatment, than PD20
cells in which the wildtype hFANCD2 or the monoubiq-
uitylation defective hFANCD2-K561R had been reintro-
duced (Figure 4C).
Next, we tested whether Cdk9 inhibitors activate ATR by
examining CHK1 Ser345P.We found that none of the Cdk9
inhibitors activate ATR at any of the indicated time points
(Figure 4D). Rather, flavo and MC295 reduced phospho-
rylation levels CHK1 Ser345P, whereas DRB did not lead
to changes in CHK1 phosphorylation (Figure 4D). Thus,
Cdk9 inhibition may lead to a decrease in CHK1 Ser345P
by an unknown mechanism. Nevertheless, the lack of ATR
activation by Cdk9 inhibitors is in stark contrast to the in-
crease in CHK1 Ser345P observed after 15 min treatment
with CPT (Figure 4D). Moreover, we analyzed the effect
of flavo and MC295 on MCM2 Serine 108 phosphoryla-
tion. This residue is also a substrate for ATR and it has
been suggested that MCM2 Serine 108 phosphorylation
recruits FANCD2 to stalled replication forks (73). How-
ever, no effect on MCM2 phosphorylation was detected af-
ter flavo orMC295 treatment (Supplementary Figure S3C).
The results indicate that early cellular response to T–R con-
flicts does not globally activate ATR, which is consistent
with the finding that TOPBP1, which is an ATR activator,
rarely colocalizes with flavo-induced FANCD2 foci (Sup-
plementary Figure S2A, B). These results suggest that T–
R conflicts trigger a distinct cellular response, which we
name the T–R conflict early (TRe) response. To analyze
whether ATR or CHK1 activity is dispensable for flavo-
induced FANCD2 focus formation, we used the ATR in-
hibitor AZ20 and CHK1 inhibitor CHIR-124 (77) at con-
centrations that inhibit their activities (Supplementary Fig-
ure S3D, E). Surprisingly, AZ20, but not CHIR-124, in-
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hibits flavo-induced FANCD2 focus formation, suggesting
that even though ATR is not activated by flavo, basal ATR
activity is required for the TRe response (Figure 4E,G).
Moreover, a dose of flavo that induces FANCD2 foci, did
not induce ATM autophosphorylation on Serine 1981 or
phosphorylation of the ATM substrate Threonine 68 in
CHK2 (Figure 4F). Treatment with ionizing radiation was
used as a positive control for ATM autophosphorylation.
Finally, ATR but not ATM inhibition also abolished flavo-
induced FANCD2 focus formation in U2OS cells (Supple-
mentary Figure S3F).
BLM and BRCA2 are involved in the early cellular response
to T–R conflicts
The BLMand FANCJ helicases are physical and/or genetic
interactors of FANCD2 (39,78,79). To address whether
BLM or FANCJ work in the TRe response, we tested
BLM−/− (80) and FANCJ−/− (81) cell lines for sensitivity
to flavo and DRB. The results show that BLM is required
for cellular survival after treatment with flavo or DRB
as well as cisplatin (Figure 5A). In contrast, FANCJ−/−
cells were not sensitive to transient treatment with the T–
R conflict-inducing drugs (Figure 5A). To further confirm
a role of BLM in the TRe response, we stably expressed
mCherry-tagged BLM in the BLM−/− cell line and quan-
tified focus formation in response to flavo treatment. BLM
focus formation after addition of flavo is similar to that of
FANCD2 with an initial increase in the number of foci fol-
lowed by a drop at later time points (Supplementary Fig-
ure S3G). A BLM−/− cell line stably expressing mCherry-
tagged BLM and endogenous Venus-tagged FANCD2 re-
vealed that flavo-induced BLM and FANCD2 foci colocal-
ize (Figure 5B, C) and that the total fluorescence intensity
of mCherry-BLM was not affected by flavo (Supplemen-
tary Figure S1E). Next, we addressed the interdependency
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of BLM and FANCD2 for flavo-induced focus formation.
The results shown in figure 5D reveal that BLM foci are
not induced by flavo in FANCD2−/− cells and vice versa
FANCD2 foci are not induced in BLM−/− cells (Supple-
mentary Figure S3H, I). Thus, BLM and FANCD2 are in-
terdependent for focus formation in response to flavo.
Previous studies have shown that mutation of the Walker
A motif of the ATP-binding site of BLM compromises
its helicase function (82,83). We investigated whether an
equivalent point mutation in chicken BLM (K663T) could
disrupt the TRe response. The number of BLM-K663T-
mCherry foci were quantified in BLM−/− DT40 cells com-
plemented with BLM-K663T-mCherry. We found that the
level of BLM-K663T foci is not affected by flavo, while a re-
duction of FANCD2 foci was observed after flavo treatment
(Supplementary Figure S4A). More importantly, the colo-
calization between BLM-K663T and FANCD2 was not
changed by flavo (Supplementary Figure S4A). Further-
more, in contrast to cells complementedwithwildtypeBLM
cDNA, BLM−/− cells expressing BLM-K663T were as sen-
sitive as cells lacking BLM after transient exposure to ei-
ther flavo or MC295 (Supplementary Figure S4B). Taken
together these results suggest that the helicase function of
BLM is required for the TRe response.
Similar to FANCD2 (21,22) and BLM (20), disruption
of BRCA2 confers increased levels of RNA–DNA hybrids
(17), suggesting that BRCA2 may also function in the TRe
response. To test this, we first used a cell line with fluores-
cent tags on endogenous BRCA2 and FANCD2 and found
that flavo induced the formation of colocalizing foci of
FANCD2 and BRCA2 (Figure 6A and Supplementary Fig-
ure S4C).Moreover,BRCA2−/− cells were hypersensitive to
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Figure 6. BRCA2 acts in concert with FANCD2 and BLM in the TRe response. (A) Quantification of FANCD2 and BRCA2 colocalizing foci in the DT40
cell line BRCA2+/TFP FANCD2+/Venus at the indicated time points after addition of 1 M flavo. Mean values and error bars representing 95% confidence
interval are indicated. Number of cells analysed is indicated (n). (B) Quantification of colony survival assay of DT40 BRCA2+/− or BRCA2−/− cells in
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flavo treatment compared to the heterozygous BRCA2+/−
control cell line (Figure 6B). Finally, BRCA2 foci were not
induced by flavo in a BLM−/− cell line but this phenotype
was rescued by introducing mCherry-tagged BLM (Figure
6C and Supplementary Figure S4D), and it was evident
that flavo-induced BRCA2 foci colocalize with BLM (Fig-
ure 6C,D). Total levels of BRCA2-YFP was not changed
within 2 hours of flavo treatment (Supplementary Figure
S1E). These results suggest that BRCA2 is part of the TRe
response together with FANCD2 and BLM.
Disruption of the TRe response manifests as DNA damage in
mitosis
Our data suggest that BLM, BRCA2 and FANCD2 work
together to promote survival after induction of T–R con-
flicts. Assuming that T–R conflicts result in genomic in-
stability in the absence of a functional TRe response, we
examined breaks and gaps on metaphase chromosomes in
flavo-treated WT and FANCD2−/− DT40 cells. Indeed, we
found that FANCD2−/− cells have an increase in chromoso-
mal aberrations after exposure to flavo for 1 h (Figure 7A).
Consistently, flavo-treated FANCD2−/− interphase cells
also displayed a small but significant increase in H2AX
foci––markingDNAdamage in chromatin (84) (Figure 7B),
indicating that T–R conflicts can result in DNA damage,
when FANCD2 is deficient.
Because flavo treatment does not trigger CHK1phospho-
rylation and therefore might not activate the G2/M check-
point, we wondered whether flavo-induced T–R conflicts
arising in very late S phase may manifest as DNA dam-
age in M phase. Thus, we analyzed the level of H2AX foci
in different phases of mitosis. In prometa- and metaphase,
FANCD2−/− cells displayed a higher level of H2AX
foci compared to WT DT40 and this is further signif-
icantly increased by flavo treatment (Figure 7C, D). In
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ana- and telophase, H2AX foci were rare in both un-
treated and in flavo-treated WT cells. In contrast, untreated
and flavo-treated FANCD2−/− cells in ana-/telophase pre-
sented H2AX foci, with the latter showing a highly signif-
icant increase in H2AX foci compared to untreated ana-
/telophase FANCD2−/− (Figure 7C, D). This demonstrates
that in FANCD2-deficient cells, flavo treatment before M
phase induces DNA damage in mitotic cells. This may ex-
plain why the G2-enriched population of FANCD2−/−,
which probably also contains some late S phase cells, was
sensitive to flavo (Figure 2B). FANCL−/− cells also present
with high levels of H2AX foci in prometaphase and
metaphase but this is not further increased by flavo. In ana-
/telophase, levels of H2AX foci in FANCL−/− cells de-
creased similar to that observed in FANCD2−/− cells and,
surprisingly, flavo treatment significantly decreases H2AX
levels in FANCL deficient cells (Figure 7C, D). Taken to-
gether these data indicate that disruption of the TRe re-
sponse manifests as DNA damage in mitosis.
Splicing inhibition triggers the TRe response
DRB and flavo both induce RNA–DNA hybrids by inhibit-
ing Cdk9 (Figure 3A–C) (64). However, RNA–DNA hy-
brids also form upon splicing inhibition (85,86). Thus, to
address whether RNA–DNA hybrids generally induce the
TRe response, we used the drug Pladienolide B (PladB),
which inhibits splicing (87). Similar to flavo, DRB and
MC295, PladB treatment induced transient FANCD2 foci,
which were not accompanied by FANCD2 ubiquitylation
or ATR activation (Supplementary Figure S4E), suggesting
that the TRe response is activated by RNA–DNA hybrids.
DISCUSSION
Here, we delineate the early cellular response to T–R con-
flicts, the TRe response, which manifests as rapid accumu-
lation of BRCA2, FANCD2 and BLM in colocalizing foci,
and acts as the first defense to avoid DNA damage and ge-
nomic instability as a consequence of T–R conflicts (Fig-
ure 7E). In this study, we have used Cdk9 inhibitors to pro-
long pausing of RNAP II at promoter proximal pause sites.
Whilst all three Cdk9 inhibitors used in this study are ATP
competitive-drugs they are structurally diverse. Flavo is a
flavonoid alkaloid andDRB is a nucleotide analog, whereas
MC295 has a thiazole core and a bulky norbonane group
that is thought to provide this drug specificity for Cdk9. Al-
though all three Cdk9 inhibitors probably can inhibit other
Cdks at high concentrations, it is highly unlikely that they
have the same off targets.
BLM and FANCD2 are interdependent for focus forma-
tion in response to flavo, which is in line with the recent find-
ing that FANCD2 and BLMare epistatic for suppression of
RNA–DNA hybrids (20). Also, BLM depends on BRCA2
for focus formation, suggesting that BRCA2, FANCD2 and
BLM work together in the TRe response. Cdk9 inhibition
triggers an initial increase followed by a drop in BRCA2,
FANCD2 and BLM foci. The decrease in FANCD2 foci af-
ter longer treatmentswith flavo orDRB is in agreementwith
previously observations (21) and is likely due to the block
to new transcription initiation. Also, 1–2 h after flavo ad-
dition, RNAP II CTD Ser5P drops. Since RNAP II CTD
Ser5P is mainly associated with promoter proximal RNAP
II (88) this observation suggests that buildup of RNAP II
at the promoters does not continue at later time points af-
ter flavo addition (Supplementary Figure S1A). The drop
in FANCD2 foci after extended flavo treatment thus indi-
cates that many spontaneous FANCD2 foci represent T–R
conflicts.
Intriguingly, we found that ATR is not globally activated
in response to drug-induced T–R conflicts. As a likely con-
sequence, T–R conflicts cause damage in mitosis when the
TRe response is disrupted. Thus, our results offer an expla-
nation for the observation that T–R conflicts lead to the per-
sistence of underreplicated regions into mitosis (7,9,24) by
showing that T–R conflicts do not elicit immediate check-
point activation. The lack of full ATR activation may have
a physiological role by ensuring that replication continues
globally, which increases the chance that stalled forks are
rescued by adjacent forks.
In line with the lack of ATR activation, we also find that
the TRe response does not involve FANCD2 monoubiq-
uitylation. FANCD2 monoubiquitylation works to engage
nucleases (89,90). Since T–R conflicts do not involve dam-
age in the DNA template, it seems plausible that the cel-
lular response avoids activation of DNA repair nucleases,
because it may have adverse effects to activate nucleases, if
the replication fork is stalled for reasons other than dam-
age in the DNA template (91). Paradoxically however, hy-
droxyurea and aphidicolin trigger FANCD2 monoubiqui-
tylation though these stresses do not directly damage the
DNA template either (27). In vitro studies suggest that
ssRNA and ssDNA can stimulate monoubiquitylation of
FANCD2 (29), whereas R loops seem to be dispensable for
aphidicolin-induced FANCD2 monoubiquitylation in cells
(28), suggesting that aphidicolin-induced monoubiquityla-
tion of FANCD2 in vivo is triggered by ssDNA formed in
response to aphidicolin rather than T–R conflicts.
A recent study using an episomal system to dissect the cel-
lular response to head-on and co-directional T–R collision
found that head-on collisions trigger the ATR-CHK1 axis
whereas co-directional collisions activate ATM (92). More-
over, co-directional collisions lead to clearance of RNA–
DNA hybrids (92). We speculate that T–R collisions in-
duced by Cdk9 inhibitors are mainly co-directional. This is
based on the finding that replication is generally co-oriented
with transcription in the human genome (93). Thus, forced
transcription pausing around transcription start sites is
likely to induce co-directional clashes. Our results show
that the TRe response does not involve global activation of
ATM or ATR. However, the previously reported responses
may reflect the outcome of prolonged T–R conflicts (92,94),
whereas we describe the early response, which may be re-
quired for clearance ofRNA–DNAhybrids that occur upon
co-directional collisions.
The involvement of FANCD2, BRCA2 and BLM in the
TRe response may account for the observation that cells
disrupted for either of these genes display elevated levels
of RNA–DNA hybrids (17,20–22,95). Notably, FANCA-
disrupted cells also accumulate RNA–DNA hybrids al-
though our work suggests that FANCA, which is part of the
FA core complex responsible for FANCD2 monoubiquity-
lation, is not part of the TRe response. Intriguingly, it has
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recently been suggested that RNA–DNA hybrids may be
susceptible to interstrand crosslinks (22,96). Therefore, we
speculate that the canonical FA pathway could be required
for the repair of RNA–DNA crosslinks, whereas FANCD2
may be involved in the removal of both crosslinked and non-
crosslinkedRNA–DNAhybrids, potentially explainingwhy
RNA–DNA hybrids also accumulate in FANCA deficient
cells.
One role of BRCA2, BLM and FANCD2 at T–R con-
flicts could be to stabilize the fork until it is rescued by a
nearby fork. However, the observation that FANCD2 dele-
tion leads to higher levels of RNA–DNA hybrids (Figure
2A,B) suggests that FANCD2 also plays an active role in re-
moving RNA–DNA hybrids or solving T–R conflict. Simi-
larly, cells depleted for BRCA2 accumulate RNA–DNA hy-
brids (17). Finally, BLM clearly has a role in the TRe re-
sponse, even though it is not involved in protecting the fork
from nucleolytic degradation (72), arguing that the TRe re-
sponse is different from fork stabilization. We have identi-
fied a role for the helicase function of BLM in the TRe re-
sponse, but it is uncertain whether BLM unwinds RNA–
DNA hybrids or acts at the replication fork. Interestingly,
BLM has previously been shown to unwind RNA–DNA
hybrids in vitro andBLMalso localizesRNA–DNAhybrids
in human cells (20). The mechanistic action of BRCA2,
BLMandFANCD2 in theTRe response is thus a subject for
future investigations, but may relate to the role of FANCD2
interaction with RNA processing factors DDX47 and hn-
RNPU that was recently described (97). Given the reported
roles in recombination of BRCA2, BLMandFANCD2 (98–
100) as well as fork protection of BRCA2 and FANCD2
(38,72), the potential role in the TRe response of the essen-
tial key recombinase and fork protector RAD51 is also an
important aspect that remains to be addressed.
FANCD2 has a well-characterized role in interstrand
crosslink repair, which involves FANCD2 monoubiq-
uitylation at lysine 561 (K563 in chicken) (33,101),
but recent studies also indicated that FANCD2 has
monoubiquitylation-independent functions (24,40,73). The
non-canonical role of FANCD2 in the TRe response could
explain these observations.
Biallelic mutations inBRCA2 (FANCD1) account for ap-
proximately 3% of FA cases (102). This subtype is asso-
ciated with higher cancer risk than most other FA sub-
types. Together with the dramatically increased cancer risk
of Bloom’s syndrome patients, this indicates that the TRe
response is a crucial mechanism to avoid carcinogenesis, re-
flecting that T–R conflicts might underlie replication stress
and genomic instability in early steps of carcinogenesis
(6,103,104). The results presented heremay have clinical im-
plications given that flavo and PladB show promising an-
ticancer activity (86,87,105–107). Our results suggest that
the TRe-response status of cancers could be used to strat-
ify drug sensitivities to flavo, PladB and other drugs with
similar mechanisms.
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